The purpose of this study is to compare the clinical outcomes of recombinant human chorionic gonadotrophin (rHCG) and urinary HCG (uHCG) in patients undergoing IVF cycles.
Urinary human chorionic gonadotrophin (u-hCG) has been widely used to induce final oocyte maturation and to trigger ovulation in assisted conception. Recombinant technology has allowed the production of r-hCG inj which all urinary contaminants are absent. Hence, this would allow the safe subcutaneous administration of a compound with less batch-to-batch variation. This study will investigate the effectiveness of the recombinant hCG compared to the currently used urinary hCG.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
150
Injection of 250 ug Ovitrelle to trigger final oocyte maturation
Injection of 5000 IU Pregnyl to trigger final oocyte maturation
Injection of 7500 IU Pregnyl to trigger final oocyte maturation
Eugonia
Athens, Greece
Percentage of mature oocytes
Percentage MII/COCs
Time frame: Day of oocyte retrieval (Day 0)
Positive test per embryo transfer
Time frame: 15 days post oocyte retrieval
Clinical pregnancy per embryo transfer
Time frame: 7 weeks of gestation
Ongoing pregnancy per embryo transfer
Time frame: 12 weeks of gestation
Level of serum hCG on day of oocyte retrieval
Time frame: Day of oocyte retrieval
Number of oocytes (COC) retrieved
Time frame: Day of oocyte retrieval
Number of mature oocytes (MII)
Time frame: Day of oocyte retrieval
Oocyte retrieval rate
Number of oocytes retrieved/number of follicles on the day of triggering final oocyte maturation
Time frame: Day of oocyte retrieval (Day 0)
Incidence of severe early OHSS
Time frame: up to Day 5 post oocyte retrieval
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.